DRUG DISCOVERY FACTORY BV

Their core work

Drug Discovery Factory BV is an Amsterdam-based pharmaceutical SME that brings drug discovery and evaluation expertise to large EU research consortia. In REACTION, they contributed to assessing the efficacy and antiviral activity of favipiravir (T-705) during the 2014-2016 Ebola epidemic — a high-urgency clinical evaluation of a candidate broad-spectrum antiviral. In ESCAPE-NET, they joined a European-scale network working on sudden cardiac arrest prevention, treatment development, and epidemiological database infrastructure. Their core value to consortia is translating laboratory and pharmacological knowledge into treatment-relevant insights across both infectious disease and cardiovascular medicine.

What they specialise in

How they've shifted over time

Their first project (REACTION, 2014–2017) addressed acute infectious disease pharmacology — specifically the emergency-context evaluation of favipiravir against Ebola, where speed and drug efficacy assessment were paramount. Their second project (ESCAPE-NET, 2017–2022) shifted to cardiovascular medicine and long-term prevention, with emphasis on genetic epidemiology, patient registries, and database infrastructure. This represents a move from urgent, single-pathogen antiviral testing toward chronic disease research with a data-driven, population-level orientation — a meaningful broadening of therapeutic scope.

Drug Discovery Factory appears to be broadening from acute infectious disease response toward cardiovascular disease, specifically areas where large patient databases, genetic epidemiology, and prevention-focused drug development intersect — a space with growing EU research investment.

How they like to work

Drug Discovery Factory has participated exclusively as a consortium partner across both projects, never serving as coordinator. Despite only two projects, they have engaged with 29 distinct partners across 13 countries — a large network that indicates they consistently join major multi-institution consortia rather than small bilateral collaborations. This pattern marks them as a sought-after specialist contributor: research networks recruit them for a specific pharmaceutical perspective that complements the academic and clinical majority.

With 29 unique partners across 13 countries from only 2 projects, Drug Discovery Factory connects consistently into large pan-European health research consortia. Their network is broad relative to their project count, suggesting they are embedded in well-funded, multi-partner RIA structures typical of EU health pillar programmes.

What sets them apart

Drug Discovery Factory occupies a specific niche as a private drug discovery SME — not a university, hospital, or CRO — participating in foundational EU research projects. This industrial perspective is deliberately recruited by academic consortia that need drug development credibility and translational relevance. Their ability to span two unrelated therapeutic areas (antiviral infectious disease and cardiovascular pharmacology) suggests adaptable pharmaceutical expertise rather than narrow single-disease specialization.

Highlights from their portfolio

• REACTION
  One of the few EU-funded rapid-response clinical evaluations of favipiravir during the 2014–2016 Ebola epidemic, making it a rare example of emergency antiviral research with direct public health urgency.
• ESCAPE-NET
  A flagship European sudden cardiac arrest network (2017–2022) combining genetic epidemiology, registry databases, and treatment research across multiple countries — one of the largest cardiovascular prevention initiatives in H2020 Health pillar.